REPROCELL spotlights the power of smarter biospecimens in new global publication
21 January 2022
REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
25 October 2021
Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.
Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine
15 September 2021
Find out more about Genetic Testing in Fetal Medicine in the upcoming REPROCELL sponsored webinar by the Society of Fetal Medicine.
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
02 September 2021
REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.
REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing
18 August 2021
Read about REPROCELL's Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing.
REPROCELL highlights the power of human fresh tissue in global publication
05 July 2021
This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
29 June 2021
Read more about REPROCELL's new Seed iPSC Manufacture Suite to provide supply for the increasing demand of iPSC-derived Master Cell Banks
REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant
21 June 2021
Reprocell will launch in Japan a new testing service of identification for Covid-19 variants including India (Delta), UK, South Africa, and Brazil variants
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
24 May 2021
The administrations of Stemchymal have been completed to all enrolled patients in phase II clinical trial for the treatment of SCA in Japan.
VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL
18 May 2021
Read more about how REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.